Stock Update (NYSE:LLY): FDA recommends no changes to Lilly’s schizophrenia injection use

[Reuters] – The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co’s schizophrenia drug after a review of two deaths. Elevated . . . → Read More: Stock Update (NYSE:LLY): FDA recommends no changes to Lilly’s schizophrenia injection use Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy Stock Update (NYSE:MRK): Merck expects to be denied approval for sugammadex injection again Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis